What this means
This is a planned trial that has not started enrolling people yet. No results exist, so it cannot tell us whether metformin helps lung function.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 40–75
- Where
- Not listed
The science
- Registered title
- Exploring the Anti-ageing Effects of Metformin in COPD
- Trial ID
- NCT06999343 ↗
- Phase
- PHASE 3
- Study type
- interventional
- Conditions
- COPD
- What is tested
- Metformin 850Mg Tab, Placebo
- Sponsor
- Fundación Instituto de Investigación Sanitaria de Navarra
- Ages
- 40 Years to 75 Years
- Dates
- First posted May 31, 2025 · updated May 31, 2025
Registry summary
Prospective, multicentre, double-blind, placebo-controlled, randomised, prospective clinical trial comparing the effect of metformin 850 mg twice daily with placebo in COPD patients with evidence of emphysema (by CT scan or reduced DLCO) who are known to have a rapid decrease in FEV1.
Main objective:
To compare the change in FEV1 at 3 years follow-up in patients receiving metformin versus placebo.
Participants will take metformin (850mg) or placebo twice daily for 3 years.